The conversation discusses the effectiveness of a hair loss treatment called CB (Breezula) in comparison to Pyrilutamide, and its potential when combined with Finasteride. There is uncertainty about when or if phase 3 trials for Breezula will begin.
RU58841 is used topically to prevent hair loss by blocking DHT, with suggestions to drink grapefruit juice, take breaks, avoid microneedling, and use lower concentrations to reduce side effects. Users discuss applying it at night to minimize systemic absorption.
A user is testing clascoterone (Winlevi) on their scalp for hair loss and has noticed a reduction in scalp sebum after one month. They are also using other unspecified treatments and plan to provide an update after the second month.
Quitting RU58841 after over two years reduced scalp itching and inflammation, despite concerns about losing hair gains. The user continues using finasteride and oral minoxidil.
HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.
Pyrilutamide is officially available for purchase, and users suggest Fluridil as an alternative topical anti-androgen. Some users report positive results with pyrilutamide from Koshine.
A 19-year-old transgender individual is experiencing worsening temple recession despite taking female hormones and 1.25mg finasteride. They are seeking advice on additional treatments to address hair loss.
The user has been using Pyrilutamide (Pyril) for hair loss for a month alongside finasteride/dutasteride since 2021 but hasn't seen results. They are considering switching to RU58841 due to its many success stories, despite being skeptical about the legitimacy and testing of Pyrilutamide.
The conversation is about a hair loss serum mix containing 5% capixyl, 3% redensyl, and procapil. The user is asking for recommendations or opinions on the effectiveness of this product.
RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.
Winlevi (clascoterone) is discussed as a treatment for hormonal acne and seborrheic dermatitis due to its ability to block DHT and regulate sebum production. The post suggests that Winlevi could offer a novel approach for managing seborrheic dermatitis.
The conversation discusses concerns about using a high concentration of 1% topical finasteride for hairline balding, with some users suggesting starting with a lower dose. It also mentions the use of GHK-CU peptide and the importance of considering the formulation to avoid excessive absorption.
A user's experience with hair loss and scalp inflammation, which was alleviated by using RU58841 along with finasteride and dutasteride. A theory of inflammation possibly being a cause of hairloss is also discussed.
User asks about CB-03-01 for hair loss treatment and mentions using topical Dutasteride, TRT, and considering mixing CB-03-01 with Fluridil. CB-03-01 is sold at a high price, and user considers trying a lower concentration.
The user experienced severe scalp itching after using RU58841 and ketoconazole shampoo, despite trying moisturizing treatments. They suspect the issue is related to the propylene glycol in the vehicle and are seeking alternatives.
Hair loss treatments, with users discussing their experiences with both RU58841 and Pyrilutamide, noting that the latter has only recently become available but may yield better results in the long term.
User considers trying RU58841 for hair loss and asks for advice on its effectiveness and application. Responses vary, with some reporting positive results and others warning about potential risks or lack of change.
The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.
RU58841 and Minoxidil can cause heart-related side effects like chest pain and heart racing. Pyrilutamide is suggested as a safer alternative, though it's new and costly.
The results of using Pyrilutamide, a hair loss treatment available on the gray market, and other treatments such as Minoxidil, Finasteride and RU58841.
The conversation discusses a 20-year-old transgender female's one-year experience with hair loss treatments, including Estradiol HRT, oral Finasteride, Bicalutamide, and Cyproterone. Specific treatments used for hair loss are oral Finasteride and potentially Estradiol as part of hormone replacement therapy.
Cetirizine 1% cream significantly improves hair growth and thickness in men with androgenic alopecia. It is considered effective, affordable, and has a low side effect profile.
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.
The user experienced significant hair loss after using RU58841, a hair loss treatment, and had to undergo a hair transplant to rectify the damage. They're asking others who've used RU58841 about their experiences, particularly if they also experienced shedding, if their hair grew back, when they started using RU, and other related questions.
The user is experiencing hair loss after a hair transplant and is considering using fluridil (Eucapil) and possibly alfatradiol as treatments, as they couldn't tolerate finasteride or minoxidil. The manufacturer of Eucapil confirmed they won't produce higher concentrations due to lack of efficacy.
The conversation is about the availability of the research chemical GT20029 for hair loss treatment and when companies like Anageninc will have it. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.